<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188796</url>
  </required_header>
  <id_info>
    <org_study_id>VITDALIZE 1.0</org_study_id>
    <nct_id>NCT03188796</nct_id>
  </id_info>
  <brief_title>The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients</brief_title>
  <acronym>VITDALIZE</acronym>
  <official_title>The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Barmherzige Brüder St. Veit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Klagenfurt am Wörthersee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Kepler University of Linz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barmherzige Brüder Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kages</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KABEG Management</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional de la Citadelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Charleroi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Mons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the VITdAL-ICU trial using a large oral dose of vitamin D3 in 480 adult critically ill&#xD;
      patients, there was no benefit regarding the primary endpoint hospital length of stay.&#xD;
      However, the predefined subgroup with severe vitamin D deficiency (25(OH)D ≤ 12ng/ml) had&#xD;
      significantly lower 28-day mortality (36.3% placebo vs. 20.4% vitamin D group, hazard ratio&#xD;
      (HR) 0.52 (0.30-0.89), number needed to treat = 6). Therefore, high-dose vitamin D3 in a&#xD;
      population of severely vitamin D deficient critically ill patients is a promising and&#xD;
      inexpensive intervention that requires confirmatory multicenter studies.&#xD;
&#xD;
      To date, only 7 interventions (e.g. noninvasive ventilation or prone positioning) have ever&#xD;
      demonstrated mortality benefit for Intensive Care Unit (ICU) patients in multicenter trials.&#xD;
      In case of benefit, vitamin D treatment in critically ill patients could be immediately&#xD;
      implemented worldwide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A very limited number of intervention trials, most including less than 30 patients, have been&#xD;
      published. The only phase III study, our VITdAL-ICU study recruited from 2010 to 2012 and&#xD;
      (n=475) did not find a difference in the primary endpoint &quot;length of hospital stay&quot; between&#xD;
      placebo and high-dose vitamin D3. However, there was a non-significant absolute risk&#xD;
      reduction in all-cause hospital mortality in the total population. The difference was larger&#xD;
      (17.5%) and significant in the predefined subgroup of patients with severe vitamin D&#xD;
      deficiency at baseline, see Kaplan Meier curve below (n=200, 28.6 vs 46.1%, p=0.01, 0.56&#xD;
      (0.35-0.90) ), corresponding to a number needed to treat of 6. (51) As this was only a&#xD;
      secondary endpoint in the predefined subgroup with severe vitamin D deficiency, this finding&#xD;
      is hypothesis generating and requires further study, leading to this application.&#xD;
&#xD;
      In our study, we were unable to identify a mechanism by which this benefit was achieved.&#xD;
      Interestingly, looking at the causes of death, the vitamin D group seemed to benefit in every&#xD;
      category.&#xD;
&#xD;
      The VITDALIZE study is a pragmatic, multicenter, placebo-controlled double-blind randomized&#xD;
      controlled phase III trial in adult critically ill patients which will be conducted in&#xD;
      academic and non-academic centers. The sponsor is the Medical University of Graz, Austria.&#xD;
&#xD;
      Subjects will be randomised in a 1:1 ratio to receive either of the two treatments:&#xD;
&#xD;
      Vitamin D: oral/enteral pharmacological dose of cholecalciferol (vitamin D3)&#xD;
&#xD;
        -  total dose 900,000&#xD;
&#xD;
        -  loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)&#xD;
           followed by 4000 IU daily (10 drops) for the entire active study period (90 days)&#xD;
&#xD;
      Placebo: identical regime - loading dose of 37.5 ml MCT followed by 10 drops daily&#xD;
&#xD;
      This study uses a group sequential design, with one interim analysis when 50% of the planned&#xD;
      enrolled patients in each arm (N=600 per arm) have completed their day 28 assessment by the&#xD;
      independent data safety monitoring board. The enrollment of patients will continue while the&#xD;
      interim analyses is performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>Length of stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalcemia at day 5</measure>
    <time_frame>Day 5 - 48 hours tolerance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmissions</measure>
    <time_frame>90 days</time_frame>
    <description>Number of readmissions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Critical Illness</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000&#xD;
loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)&#xD;
followed by 4000 IU daily (10 drops) for the entire active study period (90 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days</description>
    <arm_group_label>High Dose Vitamin D3</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  Anticipated ICU stay ≥ 48 hours&#xD;
&#xD;
          -  Admission to ICU ≤ 72 hours before screening&#xD;
&#xD;
          -  Severe vitamin D deficiency (≤12 ng/ml or undetectable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe gastrointestinal dysfunction (&gt; 400 ml residual volume)/unable to take study&#xD;
             medication&#xD;
&#xD;
          -  Do not resuscitate (DNR) order/imminent death&#xD;
&#xD;
          -  hypercalcemia&#xD;
&#xD;
          -  known recent nephrolithiasis, active tuberculosis or sarcoidosis&#xD;
&#xD;
          -  pregnancy/lactation&#xD;
&#xD;
          -  not deemed appropriate by study team/physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Amrein, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Amrein, MD, MSc</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>82383</phone_ext>
    <email>karin.amrein@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Friedel</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>72061</phone_ext>
    <email>astrid.friedel@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH Hochsteiermark Standort Bruck</name>
      <address>
        <city>Bruck An Der Mur</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johann Kainz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Enzenbach</name>
      <address>
        <city>Enzenbach</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otmar Schindler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Feldbach</name>
      <address>
        <city>Feldbach</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Watzinger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Fürstenfeld</name>
      <address>
        <city>Fürstenfeld</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Krippl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Amrein, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Joannidis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum am Wörthersee</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Likar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Hochsteiermark Standort Leoben</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Wutzl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barmherzige Brüder Konventhospital Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Clodi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Reisinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Meier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Schwarzach</name>
      <address>
        <city>Schwarzach Im Pongau</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Wimmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barmherzige Brüder</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Schmutz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schellongowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Villach</name>
      <address>
        <city>Villach</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ernst Trampitsch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Spital Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Schmaldienst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Charles Preiser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime van Cutsem</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Fraipont</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain D´hondt</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Amrein K, Schnedl C, Holl A, Riedl R, Christopher KB, Pachler C, Urbanic Purkart T, Waltensdorfer A, Münch A, Warnkross H, Stojakovic T, Bisping E, Toller W, Smolle KH, Berghold A, Pieber TR, Dobnig H. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014 Oct 15;312(15):1520-30. doi: 10.1001/jama.2014.13204. Erratum in: JAMA. 2014 Nov 12;312(18):1932.</citation>
    <PMID>25268295</PMID>
  </reference>
  <reference>
    <citation>Amrein K, Christopher KB, McNally JD. Understanding vitamin D deficiency in intensive care patients. Intensive Care Med. 2015 Nov;41(11):1961-4. doi: 10.1007/s00134-015-3937-4. Epub 2015 Jul 4.</citation>
    <PMID>26142054</PMID>
  </reference>
  <reference>
    <citation>Amrein K. Vitamin D status in critical care: Contributor or marker of poor health? Lung India. 2014 Jul;31(3):299-300.</citation>
    <PMID>25125826</PMID>
  </reference>
  <reference>
    <citation>Amrein K, Papinutti A, Mathew E, Vila G, Parekh D. Vitamin D and critical illness: what endocrinology can learn from intensive care and vice versa. Endocr Connect. 2018 Dec 1;7(12):R304-R315. doi: 10.1530/EC-18-0184. Review.</citation>
    <PMID>30352414</PMID>
  </reference>
  <reference>
    <citation>National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, Hayden D, Hough CL, Hyzy RC, Khan A, Levitt JE, Park PK, Ringwood N, Rivers EP, Self WH, Shapiro NI, Thompson BT, Yealy DM, Talmor D. Early High-Dose Vitamin D(3) for Critically Ill, Vitamin D-Deficient Patients. N Engl J Med. 2019 Dec 26;381(26):2529-2540. doi: 10.1056/NEJMoa1911124. Epub 2019 Dec 11.</citation>
    <PMID>31826336</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>critical care</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

